






Overview Cough Background Natural History of symptoms Protracted bacterial Bronchitis Diagnosis Microbiology Treatment of exacerbations Long term management Future directions














Protracted Bacterial Bronchitis • >4 weeks of cough — Initially managed as asthma — Shorter courses of antibiotics does not seem to clear — 2-4 weeks of Abs needed • Microbiology — Haemophilus influenzae 40% — Streptococcus pneumoniae 20% — Staphylococcus aureus 7.6% — Moraxella catarrhalis 8.5% — Pseudomonas aeruginosa 7.9%

Pizzutto 2017


Resolution A positive response to a full course of an appropriate antibiotic and the child returning to completely good health confirms the diagnosis of PBB and no further investigations is likely to be needed. Stepwise approach to further investigation







Diagnosis Early diagnosis is important progressive, long term morbidity early bronchiectasis in paediatrics can be reversible · When to consider investigating for BE - chronic wet cough in children - red flag signs - cough pointers Investigations Gaillard et al. Radiol 2003 Haidopoulou et al. Pediatr Pulmonol 2009 TSANZ Guidelines 2015 Goyal et al. Arch Dis Child 2015 Chang, Chest 2017



Radiology

- · Bronchial wall dilation is the characteristic feature of bronchiectasis.
- The BA ratio
- increases with age in adults
- lower threshold is recommended in children



BTS guidelines Thorax 2010 Kapur et al. Chest 2011 Kuo et al. Chest 2017

Viruses

- Respiratory viruses were identified in 48% of exacerbations in 69 Queensland children with bronchiectasis $\,$
- Detected in the BAL of 44% of 68 clinically stable children
- · Rhinovirus most common

Pizzutto et al. Plos one 2015 Kapur et al. Arch Dis Child. 2014


Exacerbations

- Important
- Independent risk factor for lung function decline
- Huge economic burden
- Associated with poor quality of life
- Definition
- New wet cough for more than 3 days
- Increase in sputum volume
- Change in sputum colour

Kapur et al. Pediatr Pulmonol 2012 Kapur et al. Chest 2012


Treatment Options

- Antibiotics
- · Airway clearance therapy
- · Muco-active agents
- · Asthma therapies
- Steroids/ bronchodilators- combinations
- Vaccines
- · Prophylactic antibiotics




Antibiotics Cornerstone of therapy Treatment paradigm IV if not responding to oral abs Oral vs IV antibiotic efficacy studies not available Equivalence between antibiotics established Length of treatment to extend of 4 weeks also shown to improve and clear symptoms If oral antibiotics used, clinical review required to assess response

BEST -2 Study Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial Was Coyal, Kelli Camusod, Catherer A Byene, Peter Sidern, I Beert Master, Robert SWare, Cabralle MACCHING, Machinel Birds, John M. Robert Sware, Cabralle Sware, Sware SWare, Cabralle MacChing, Machinel Birds, John M. Robert Sware, Cabralle Sware, Sware SWare, Cabralle Sware, Sware SWare, Cabralle Sware, Sware



Pseudomonas eradication Nil consistency in managing Pseudomonas aeruginosa 14-day IV ceftazidime & tobramycin, followed by nebulised tobramycin or placebo for 3 months 54.5 % free of P. aeruginosa at 12 months vs 29.4% placebo. Retrospective studies: 64 patients who had additional 3 months of colistin eradication rate at 6 months was 52% (n=33), and 70% (n=23) at 12 months chronic P. aeruginosa infection- addition of neb tobramycin to high-dose oral ciprofloxacin for 14 days –better microbial clearance at day 14



Bronchodilators

- · No paediatric studies
- Many patients are wrongly diagnosed as asthma before a diagnosis of bronchiectasis is made
- Wheeze can be a feature of bronchiectasis exacerbation
- In the absence of a confirmed diagnosis of asthma, not recommended

Children's Health Queensland

Vaccines

- Role of Influenza and Pneumococcal vaccines have not been systematically studied
- · Potential vaccines
- PsA vaccine
- NTHi vaccine
- 10-valent pneumococcal-H.influenzae protein D conjugate vaccine in children with chronic suppurative lung disease and bronchiectasis
 - o preliminary data shows reduction in antibiotic treated exacerbations

Ildren's Health Queensland

Treatment Options

- Antibiotics
- · Airway clearance therapy
- · Muco-active agents
- Asthma therapies
- Steroids/ bronchodilators- combinations
- Nutrition
- Vaccines
- · Prophylactic antibiotics



Monitoring and on-going care

- · Clinical review
- Lung function
- Microbiology
- · Individualized management plans
- · Multidisciplinary approach

idren's Health Queensland

Registries

- American bronchiectasis registry
- EMBARC
- NZ bronchiectasis registry
- Australian Bronchiectasis registry



Summary

- Management principles are similar to other chronic lung diseases
- Specific updates on management
- · Antimicrobial therapy
- AcuteLong term
- · Airway clearance therapy
- Other potential therapies
- Treatment evidence from CF not readily applies to bronchiectasis
- · Ongoing research is required

Children's Maylth Quanneland

